Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, 300060, China.
Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute, and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Acta Pharmacol Sin. 2023 Dec;44(12):2525-2536. doi: 10.1038/s41401-023-01133-3. Epub 2023 Jul 20.
Heat shock protein family A member 8 (HSPA8) participates in the folding or degradation of misfolded proteins under stress and plays critical roles in cancer. In this study, we investigated the function of HSPA8 in the development of liver cancer. By analyzing the TCGA transcriptome dataset, we found that HSPA8 was upregulated in 134 clinical liver cancer tissue samples, and positively correlated with poor prognosis. IHC staining showed the nuclear and cytoplasmic localization of HSPA8 in liver cancer cells. Knockdown of HSPA8 resulted in a decrease in the proliferation of HepG2 and Huh-7 cells. ChIP-seq and RNA-seq analysis revealed that HSPA8 bound to the promoter of pleckstrin homology-like domain family A member 2 (PHLDA2) and regulated its expression. The transcription factor ETV4 in HepG2 cells activated PHLDA2 transcription. HSPA8 and ETV4 could interact with each other in the cells and colocalize in the nucleus. From a functional perspective, we demonstrated that HSPA8 upregulated PHDLA2 through the coactivating transcription factor ETV4 to enhance the growth of liver cancer in vitro and in vivo. From a therapeutic perspective, we identified both HSPA8 and PHDLA2 as novel targets in the treatment of HCC. In conclusion, this study demonstrates that HSPA8 serves as a coactivator of ETV4 and upregulates PHLDA2, leading to the growth of HCC, and is a potential therapeutic target in HCC treatment.
热休克蛋白家族 A 成员 8(HSPA8)在应激条件下参与错误折叠蛋白的折叠或降解,在癌症中发挥着关键作用。在本研究中,我们研究了 HSPA8 在肝癌发展中的功能。通过分析 TCGA 转录组数据集,我们发现 134 例临床肝癌组织样本中 HSPA8 上调,与预后不良呈正相关。免疫组化染色显示 HSPA8 在肝癌细胞中定位于核和细胞质。HSPA8 敲低导致 HepG2 和 Huh-7 细胞增殖减少。ChIP-seq 和 RNA-seq 分析表明,HSPA8 结合于 pleckstrin homology-like domain family A member 2(PHLDA2)的启动子并调节其表达。转录因子 ETV4 在 HepG2 细胞中激活 PHLDA2 转录。HSPA8 和 ETV4 可以在细胞内相互作用并在核内共定位。从功能角度来看,我们证明 HSPA8 通过共激活转录因子 ETV4 上调 PHLDA2,从而增强肝癌在体外和体内的生长。从治疗角度来看,我们确定 HSPA8 和 PHLDA2 均为 HCC 治疗的新靶点。总之,本研究表明 HSPA8 作为 ETV4 的共激活因子,上调 PHLDA2,导致 HCC 生长,是 HCC 治疗的潜在治疗靶点。